ETH Meets Boston 2019

Boston, 18 October 2019 - RETHINK Drug Discovery. This public event will address the latest advances in the field of artificial intelligence and drug discovery.

ETH_Meets_Boston2019

RETHINK Drug Discovery

Recent advances in chemical synthesis, biological testing, and artificial intelligence (AI) allow for greater automation in the drug discovery process. AI systems that generate novel design suppositions, as well as, cope with multiple design objectives provide a basis for further automation in some aspects of drug discovery. Automation could potentially accelerate timeframes for compound design and optimization. It could also enable better decision making in early-stage pharmaceutical discovery that translates into late-stage clinical validation. However, such approaches also raise considerable conceptual, technical, and organizational challenges.

This symposium aims to address the latest advances of this rapidly progressing field of science, by bringing together leading researchers to present the state-of-the-art in drug discovery. Together they will make daring predictions surrounding the possibilities and limitations of drug discovery using machine intelligence.

Public event
Friday, October 18, 2019
6.30 pm

Door opening time: 6.00 pm

Venue

external page District Hall
75 Northern Avenue, Boston, MA

RSVP

Free entry. Please register external page here.

Programme

Download Download (PDF, 598 KB)

 

Moderator

external page Susan Kish
Executive, entrepreneur, advisor

Speakers

external page Aimee Usera
Senior Investigator, Novartis Institutes for BioMedical Research (NIBR)

Gisbert Schneider
Professor for Computer-Assisted Drug Design, ETH Zurich

external page Connor W. Coley
Postdoc, Broad Institute, MIT

external page Marcie Glicksman
Chief Scientific Officer, ORIG3N

JavaScript has been disabled in your browser